Related Experiment Videos
Use of antithrombotic measures for stroke prevention in atrial fibrillation
1Orpington Stroke Unit, Bromley Hospitals NHS Trust, Kent, UK.
Insights
Antithrombotic medication use for stroke prevention in atrial fibrillation patients is often inappropriate, with many high-risk individuals undertreated. Age should not be the primary factor; risk assessment is crucial for effective anticoagulation.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation increases stroke risk.
- Antithrombotic therapy is key for stroke prevention in atrial fibrillation.
- Current antithrombotic prescribing patterns require evaluation.
Purpose of the Study:
- To assess the appropriateness of antithrombotic drug use in atrial fibrillation patients.
- To compare current antithrombotic prescribing with established clinical guidelines.
Main Methods:
- 344 atrial fibrillation patients were clinically assessed for stroke risk and contraindications.
- Anticoagulation needs were determined using pooled clinical trial data.
- Warfarin and aspirin use was compared against recommended anticoagulation protocols.
Main Results:
- 14% low, 62% moderate, and 24% high stroke risk identified.
- Anticoagulation was indicated for 75% of patients by some criteria, but only 21% by others.
- 42% of moderate-to-high risk patients received no antithrombotics; 27% of low-risk patients were overtreated.
Conclusions:
- A significant gap exists in appropriate anticoagulation for high-risk atrial fibrillation patients.
- Antithrombotic therapy is underutilized in eligible patients and overutilized in low-risk patients.
- Risk assessment, not age, should guide anticoagulation decisions; consensus on practice is needed.
Objective:
To evaluate appropriateness of antithrombotic use to prevent stroke in atrial fibrillation.
Design, Patients:
344 patients with atrial fibrillation, stratified by age, were assessed clinically for contraindications to anticoagulation and stroke risk. The use of warfarin and aspirin was compared with recommendations for anticoagulation derived from pooled clinical trial data.
Results:
Low risk of stroke was seen in 47 (14%) patients, moderate risk in 213 (62%), and high risk in 84 (24%) patients included in the sample (mean (SD) age 68.4 (17.2) years, 42% men). The proportion of patients requiring anticoagulation varied from 258/344 (75%) to 72/344 (21%) depending upon criteria used, of whom 86/258 (33%) and 36/72 (50%) were receiving warfarin, respectively. Warfarin or aspirin were not being used in 124/297 (42%) patients with moderate to high risk, whereas anticoagulation was being undertaken in 13/47 (27%) patients at low risk of stroke. Antithrombotic use (warfarin or aspirin) was significantly less common in patients over 75 years of age, regardless of absence of contraindications and eligibility according to various criteria (p < 0.001).
Conclusions:
A clear need for anticoagulation using clinical criteria existed in about 25% of patients in atrial fibrillation presenting to medical clinics who were at high risk of stroke. Of these, only 50% of eligible patients were being anticoagulated. Appropriate anticoagulation needs to be based on risk assessment rather than age. Consensus is therefore needed on appropriate antithrombotic use in clinical practice.